Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

gies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the development, therapeutic potential, and potential safety and efficacy of MAP Pharmaceuticals' MAP0004 product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the enrollment, conduct, completion and reporting of clinical trials, as well as risks relating to failure to achieve favorable clinical outcomes, and that MAP0004 will not be approved for commercial use by the United States Food and Drug Administration. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2008, and available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... (PRWEB) November 21, 2014 Prominent ... investors will gather on December 3rd at Genetic ... Conferences series. GeneticRx will take place at the ... School and will discuss the present and future ... exon skipping, and gene editing—as well as the ...
(Date:11/22/2014)... 22, 2014 Respiratory therapy students ... proper management of life-like respiratory ailments using the ... . Grand Rapids-based, Michigan Instruments Inc. developers of ... of the respiratory simulation units to the pro-gram, ... Valley and Muskegon Community College are collaborating to ...
(Date:11/21/2014)... USA (PRWEB) November 19, 2014 The ... our lives was shared with more than 200 primary ... postgraduate students from the University of Otago Physics Department ... . The Otago students, members of the university’s OSA/SPIE ... Zealand in early September, giving children from small, rural ...
(Date:11/21/2014)... The November 2014 issue of BioTechniques ... access journal featuring the following articles:, , ... photoresponsiveness in the retina , DNA from ... using chromogenic substrates in zebrafish , Re-use ... electrophoresis , Nuclear LC3-positive puncta in stressed ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3
... ST. LOUIS, Jan. 20, 2012   On Tuesday, January ... will vote on a shareholder proposal to create a ... with its chemical products and genetically modified organisms (GMOs). ... strongest signals to date that the biotech food conglomerate ...
... PORTLAND, Ore., Jan. 20, 2012 Boulder Diagnostics Inc. ... into a license and collaboration agreement to develop rapid ... a highly specific dye technology developed at PSU. Under ... Department of Chemistry, and PSU will be entitled to ...
... Berkeley, CA A team of scientists from Bio ... the feedstocks for advanced biofuels and renewable chemicals production ... to extract the all the major sugars in seaweed ... making seaweed a cost-effective, renewable source of biomass. ...
Cached Biology Technology:Monsanto Attempts to Lockout Socially Responsible Shareholder at Annual Meeting 2Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University 2Bio architecture lab technology converts seaweed to renewable fuels and chemicals 2
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... Nov. 3, 2014 Research and Markets ... Therapy - Technologies, Markets and Companies" to their offering. ... technologies and methods, which have already started to play an ... transplantation is replacing the old fashioned bone marrow transplants. Role ... is bound to become a part of medical practice. ...
(Date:11/3/2014)... Nov. 3, 2014  NeuroSigma ® , Inc. ... sciences company focused on commercialization of its non-invasive ... the treatment of neurological and neuropsychiatric disorders, announced ... has issued a Notice of Allowance for Mexican ... co-owned by NeuroSigma and the Regents of the ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... the impact of student research on life at American University,s ... Following a 2009 study at American University,s main dining ... dishes used when trays were removed, trays have mostly gone ... the first time, a new paper coauthored by AU professor ...
... Houston faculty members have been named Charter Fellows of ... contributions to scientific and technological innovation. UH faculty ... Paul Chu, a physics professor and chief scientist of ... Dan Luss, a professor in chemical and biomedical engineering, ...
... (H2S) may play a wide-ranging role in staving off ... print in the journal Molecular and Cellular Biology ... explores the compound,s plethora of potential anti-aging pathways. ... important endogenous signaling molecule because of its significant effects ...
Cached Biology News:Going trayless study shows student impact 2Going trayless study shows student impact 3National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3Hydrogen sulfide: The next anti-aging agent? 2